SCHEMBL1268653

SCHEMBL1268653

Cc1nc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ncc1Oc1ccc(S(=O)(=O)N2CCOCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.45
▸ LMNA P02545 5/20 0.45
▸ ALDH1A1 P00352 6/20 0.44
▸ GLA P06280 1/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ HTT P42858 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ NOD2 Q9HC29 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1268801 0.90 ALDH1A1 (0.52) SMN1; SMN2LMNAALDH1A1GLAKMT2A
SCHEMBL1269492 0.90 GAA (0.48) SMN1; SMN2LMNAALDH1A1GLAHSD17B10
SCHEMBL12931666 0.84 ALDH1A1 (0.45) SMN1; SMN2LMNAALDH1A1GLAKMT2A
SCHEMBL1268839 0.83 MEN1 (0.42) SMN1; SMN2LMNAALDH1A1GLAKMT2A
SCHEMBL1268921 0.81 PPARG (0.48) PPARG
SCHEMBL1269625 0.78 ALDH1A1 (0.51) SMN1; SMN2LMNAALDH1A1GLAKMT2A
SCHEMBL1269442 0.77 ALDH1A1 (0.50) SMN1; SMN2LMNAALDH1A1GLAL3MBTL1
SCHEMBL1269394 0.74 ALDH1A1 (0.42) SMN1; SMN2LMNAALDH1A1KMT2AMEN1
SCHEMBL1269704 0.73 GAA (0.46) SMN1; SMN2LMNAALDH1A1KMT2AMAPT
SCHEMBL1269715 0.72 MEN1 (0.43) SMN1; SMN2LMNAALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG SMN1; SMN2 4836/4885LMNA 2576/4885ALDH1A1 2237/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG SMN1; SMN2 4836/4885LMNA 2576/4885ALDH1A1 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback